EP4146221A1 — Treatment of hyperuricemia
Assigned to Frederiksberg Hospital · Expires 2023-03-15 · 3y expired
What this patent protects
The present invention relates to methods for treatment of hyperuricemia using GLP-1 receptor agonists. The invention is based on a double-blinded, placebo controlled study in overweight and obese patient where a significant urate lowering was observed in subjects with increased s…
USPTO Abstract
The present invention relates to methods for treatment of hyperuricemia using GLP-1 receptor agonists. The invention is based on a double-blinded, placebo controlled study in overweight and obese patient where a significant urate lowering was observed in subjects with increased serum urate levels.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.